SunGlowInnovations

SunGlow Innovations

Development

Three independent programs across human and veterinary research.

IND 184255

United States · Human

SunGlow Innovations LLC is preparing an early clinical study of CDX-101 in adults with advanced extracranial solid tumors.

FDA pre-IND written feedback

Documented development milestone

Original IND receipt date recorded by FDA

Documented development milestone

Protocol v3.0 and responses to clinical and clinical pharmacology comments prepared in sequence 0006

Phase 1 planning

U.S. FDA clinical development timeline

The U.S. and China programs advance in parallel. Enrollment, follow-up and preparation for the next stage are planned together to maintain continuity.

50+Cumulative enrollment target

  1. 2026–2027

    Phase 1 start-up and early enrollment

    Use the U.S. IND protocol to open the safety lead-in and track safety and response from the first participant.

  2. 2027

    Sequential enrollment and expansion

    Continue the U.S. development program toward at least 50 cumulative participants, with follow-up running alongside cohort expansion.

  3. 2027–2028

    Confirmatory studies and filing preparation

    Plan confirmatory studies in sequence and prepare the submission package in parallel with ongoing follow-up.

  4. Q4 2027 or H1 2028

    Target marketing application filing

    Target submission of a U.S. marketing application to the FDA.

Sponsor planning targets. Sequence and timing depend on study results and required regulatory reviews.

CVM INAD I-014155

United States · Veterinary

The veterinary program is exploring intratumoral research in companion animals with spontaneous solid tumors, including dogs and cats. Study design and veterinary collaborations are in development.

Pet oncology
CVM receipt date for the INAD opening submission

Documented development milestone

Submitted the expanded conditional approval (XCA) eligibility request. The CVM portal shows that the center sent a response.

Documented development milestone

Submitted target animal safety (TAS) materials for chlorine dioxide injection in dogs and cats. The CVM portal shows that the center sent a response.

Investigational development

2027 U.S. veterinary development roadmap

Sponsor forecast for INAD I-014155 covering XCA eligibility, target animal safety, manufacturing, CMC, effectiveness and the conditional approval application.
Accelerated scenario forecast prepared by the sponsor. The dates are planning targets and FDA determines the review outcome and timing. View full-size roadmap

China drug IND

China · Human

WanBinCell is preparing the requested supplementary dossier materials. Beijing Hospital is the planned research institution.

Application-material supplementation notice dated

Documented development milestone

Supplementary dossier package prepared

Application supplementation

China clinical development timeline

The U.S. and China programs advance in parallel. Enrollment, follow-up and preparation for the next stage are planned together to maintain continuity.

200+Cumulative enrollment target

  1. 2026–2027

    Phase 1 start-up and early enrollment

    Advance the China IND pathway and site start-up, then begin enrollment under the applicable protocol.

  2. 2027

    Sequential enrollment and expansion

    Continue the China development program toward at least 200 cumulative participants, with follow-up running alongside cohort expansion.

  3. 2027–2028

    Confirmatory studies and filing preparation

    Plan confirmatory studies in sequence and prepare the submission package in parallel with ongoing follow-up.

  4. Q4 2027 or H1 2028

    Target marketing application filing

    Target submission of a marketing application in China on the same schedule.

Sponsor planning targets. Sequence and timing depend on study results and required regulatory reviews.

What an IND reference means

An investigational new drug (IND) application concerns use of an investigational drug in a proposed clinical investigation. IND 184255 identifies the CDX-101 regulatory file. Receipt, an effective IND, ethics approval, site activation and marketing authorization are separate milestones.

FDA IND procedures